This is the first book published that focuses on competition law and
policy in the Japanese pharmaceutical sector. It consists of chapters
written and edited by academics who research the industry from various
perspectives, including economics, competition law, pharmaceutical
regulations, and intellectual property law.
Competition policies involving pharmaceutical products attract attention
from academics and policymakers worldwide. The pharmaceutical industry
is regulated by drug laws that vary from country to country and are
affected by differing practices and industrial structures. The book
begins by examining drug regulations and trade practices in the industry
that are peculiar to Japan and its healthcare system. It then presents
the Japanese Antimonopoly Act and cases involving it, and discussions of
current competition law issues in the Japanese pharmaceutical industry.
The book also discusses innovation and intellectual property and
economic analyses of pharmaceutical regulations and drug discovery. The
chapters include comparative studies on Japanese regulations vs. those
in the European Union and the United States.
Japan is one of the biggest pharmaceutical markets in the world. With
this in mind, the book provides "one-stop shopping" for anyone
interested in pharmaceutical regulations in the country. Covering the
basics but extending to in-depth explorations of complex problems, this
book appeals not only to students and academics, pharmaceutical
companies and regulators, but also to those dealing with real-world
policy issues that encompass competition policy, intellectual property,
and pharmaceutical regulation.
Chapter 11 is available open access under a Creative Commons Attribution
4.0 International License via link.springer.com
